Related Publications
Visonà G, …, Wenger KJ. Machine-Learning-Aided Prediction Of Brain Metastases Development In Non-Small Cell Lung Cancers. Clinical Lung Cancer August 2023
Put, P.*, Alcicek, S* et al. Detection of pyridine derivatives by SABRE hyperpolarization at zero field. Commun Chem 2023
Alcicek, S et al. Zero- to low-field relaxometry of chemical and biological fluids. Commun Chem 2023
Thomas C et al. Whole-brain water content mapping using Super-resolution reconstruction with MRI acquisition in 3 orthogonal orientations Magn. Resonance in Med. 2021
Alcicek S et al. Zero-Field NMR J-Spectroscopy of Organophosphorus Compounds. J Phys Chem Lett. 2021
Alcicek S et al. Zero-Field NMR of Urea: Spin-Topology Engineering by Chemical Exchange. J Phys Chem Lett. 2021
Voss M, Wenger KJ, et al. Single-shot Bevacizumab for Cerebral Radiation Injury. BMC Neurology. 2021
Voss M, Wenger KJ, et al. Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial. Eur J Nutr. 2021
Wick A, …, Wenger KJ, …, Tabatabai G. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clin Cancer Res. 2021
Senft C, …, Wenger KJ, …, Forster M-T. The ability to return to work: a patient-centered outcome parameter following glioma surgery. J Neurooncol. 2020
Voss M, …, Wenger KJ, … C, Rieger J. ERGO2: A prospective randomized trial of calorie restricted ketogenic diet and fasting in addition to re-irradiation for malignant glioma. Int J Radiat Oncol Biol Phys. 2020
Wenger, KJ et al. Lower Lactate Levels and Lower Intracellular pH in Patients with IDH -Mutant versus Wild-Type Gliomas. AJNR Am J Neuroradiol 2020
Wenger, KJ et al. Non-Invasive Measurement of Drug and 2-HG Signals Using 19F and 1H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032. Cancers 2020
Wenger, KJ et al. Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial. Cancers 2020
Wenger, KJ et al. Fitting algorithms and baseline correction influence the results of non-invasive in vivoquantitation of 2-hydroxyglutarate with 1H-MRS. NMR in Biomedicine 2019
Wenger KJ et al. In vivo Metabolic Profiles as Determined by 31P and short TE 1H MR-Spectroscopy : No Difference Between Patients with IDH Wildtype and IDH Mutant Gliomas. Clin Neuroradiol. 2019
Wenger, KJ et al. Intracellular pH measured by 31P-MR-spectroscopy might predict site of progression inrecurrentglioblastoma under antiangiogenic therapy. J Magn Reson Imaging 2017
Wenger KJ, et al. Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncol Lett. 2017
The full list of publications is available at https://bit.ly/Pubmed_Publications
Available Hardware
3 Tesla MR-Scanner: Siemens Prisma:
Equipment:
1-Channel CP head coil with mirror system
20-Channel phased array head/neck coil with mirror system
32-Channel head coil with mirror system
64-Channel head/neck coil with mirror system
31P/1H head coil for spectroscopy
31P/1H surface coils size S and M for spectroscopy
Funding
|
04/2023 |
Main applicant K. Wenger Support line “Research infrastructure” of Johanna Quandt Young Academy (JQYA) and Goethe University Frankfurt, Career Support for R3 Researchers 7500 € consumables |
|
04/2022-03/2025 |
Main applicant S. Alcicek Medical Scientist Program Mildred-Scheel-Nachwuchszentrum (MSNZ) |
|
01/2022-01/2025 |
Main applicant K. Wenger Else Kröner-Fresenius-Stiftung (EKFS) Erstantrag 193.290 € scientific equipment and salaries Research Topic: MR-spectroscopic in vivo metabolic profiling – a novel “omic” in the multiomics assessment of diffuse large B-cell lymphoma
|
|
10/2021-10/2024 |
Main applicant K. Wenger Clinician Scientist Fellowship Program Mildred-Scheel-Nachwuchszentrum (MSNZ) funding of own position for three years (100%, 50%, 50%) in addition to 10.000 € for scientific equipment and other expenses) Research Topic: MR-spectroscopic in vivo metabolic profiling – a novel “omic” in the multiomics assessment of diffuse large B-cell lymphoma
|
|
07/2019 |
Main applicant K. Wenger Research Stipend Frankfurter Forschungs Förderung (FFF) Nachwuchsgruppe 66.000 € scientific equipment and other expenses Research Topic: Predictive value of combining imaging, clinical and genomic metrics for development of brain metatases in non-small cell lung cancer patients
|
|
07/2016 – 07/2017 |
Main applicant K. Wenger Research Stipend Frankfurter Forschungs Förderung (FFF) Patenschaftsmodell funding of own position for one year in addition to 24.000 € for scientific equipment and other expenses Research Topic: Non-invasive identification and therapy monitoring of IDH mutations in glioma patients using 1H/31P MR Spectroscopy |
Internal and External Research Partners
Professor Dr. med. Joachim Steinbach, Head of the Dr. Senckenberg Institute of Neurooncology at the University Hospital Frankfurt and colleagues
Professor Dr. med. Marcus Czabanka, Head of the Institute of Neurosurgery at the University Hospital Frankfurt and colleagues
Professor Dr. Harald Schwalbe, Head of the Center for Biomolecular Magnetic Resonance (BMRZ) at the Goethe Universität Frankfurt and colleagues
Professor Dr. med. Thomas Oellerich, DKTK Professorship for Translational Proteome Research in Cancer at the University Hospital Frankfurt
Professor Dr. Florian Buettner, DKTK Professorship for Bioinformatics in Oncology, German Cancer Consortium at the University Hospital Frankfurt